3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
Carboplatin
71
pembrolizumab
70
Pemetrexed
62
Cisplatin
46
Nivolumab
28
Paclitaxel
27
durvalumab
26
Specimen Handling
25
osimertinib
23
Docetaxel
23
Magnetic Resonance Spectroscopy
21
Gemcitabine
17
Cetuximab
15
130-nm albumin-bound paclitaxel
15
atezolizumab
14
amivantamab
14
Radiotherapy
12
Radiosurgery
12
lazertinib
11
Ipilimumab
9
Bevacizumab
9
cemiplimab
8
Taxes
8
Drug Therapy
8
alectinib
7
Ramucirumab
7
Observation
7
Radiation
6
Leucovorin
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.